Serotonin receptors (5-HTR)
A variety of 5-HTergic functions is accomplished by the release of 5-HT in targeted areas and its action via at least 14 different pre-and postsynaptic 5-HTR [38] . As shown in Tables   1 and 2 , 5-HTR are subdivided according to their distribution, molecular structure, cell Stimulation of receptors by antipsychotics increase prefrontal cortical dopamine release 61
Negative correlation between receptor binding potential and cognitive function in healthy persons 55
Decreased receptor number or density in elderly with MCI and AD 57 Relationship between receptor number and BPSD 58
No correlation between receptor binding potential and cognitive function in healthy persons 56
Receptors affect declarative and non-declarative memory functions via glutamatergic, cholinergic and GABAergic neurons 49
Receptors regulate different kinases and immediate early genes implicated in memory formation 49
Decreased receptor binding in amygdala of patients with schizophrenia 60
Increased receptor binding in prefrontal cortex of patients with schizophrenia 60
No change in brain receptor binding in patients with schizophrenia 60
Activation of postsynaptic receptors in rodents impairs emotional memory through attenuation of neuronal activity 53
Activation of presynaptic receptors reduces 5-HT release and exerts pro-cognitive effects on passive avoidance retention 53
Potential of 5-HTR 1A and DR 2 heterodimers in the frontal cortex for cognitive enhancement 62
5-HT 1B Receptor agonist reduces cognitive function in experimental animals 66
Decrease in receptor binding potential with aging in healthy subjects 65
Role of receptor inverse agonists and antagonists in treatment of damaged memory and cognitive processes 66
Decrease in receptor density in frontal and temporal cortex associated with cognitive dysfunction in patients with AD 67
Decrease in receptor binding in brain stem associated with good response to psychotherapy in depressive patients 69
Positive correlations between creative ability, a measure of divergent thinking, and average receptor availability in grey matter 64
Increased receptor mRNA levels in the hippocampal formation in patients with schizophrenia 70
Receptor agonists induce potentiation of latent inhibition, a characteristic of antipsychotics 71 5-HT 2A Decreased receptor number in hippocampus and frontal cortex with aging correlates with cognitive decline 27 Severity of cognitive impairment in AD patients correlates with the decrease in receptor binding 77, 78 Link between gene variant of the 5-HTR 3E subunit and sustained attention in schizophrenic patients 114
Blockade of receptors protects neurons against Ab-induced neurotoxicity by inhibition and stimulation of glutamate and acetylcholine release, respectively The presence of 5-HTR 2C in the limbic system, frontal cortex, and hippocampus suggests their possible involvement in schizophrenia [98] . Preclinical data revealed that 5-HTR 2C modulation of cognitive symptoms might have beneficial effects in schizophrenia, as well [99] . The 5-HTR 3 antagonists, such as ondansetron, are mainly used for the treatment of chemotherapy-induced emesis [101] . However, they have been also shown to improve cognition in different models of memory impairment [102] . Boast et al. [103] reported that ondansetron improves radial arm maze performance in MK801-impaired rats, suggesting its cognition enhancing properties.
Ondansetron also blocked scopolamineinduced learning deficits [104] , whereas another 5-HTR 3 antagonist itasetron showed memory-enhancing effects [105] . 5-HTR 6 agonism has also been reported to facilitate emotional learning by promoting the neuronal plasticity in the caudate putamen, hippocampus, and prefrontal cortex [161] .
In animal models of schizophrenia, the activation of 5-HTR 6 was associated with the stimulation of the mTOR (mammalian Target of Rapamycin) signalling pathway in prefrontal cortex. Rapamycin, the mTOR inhibitor, prevented cognitive deficits induced by 5-HTR 6 agonists [162] . Improvements in episodic memory, social cognition, executive function, and working memory were also observed following administration of 5-HTR 6
antagonists in preclinical trials [163] . There are also reports showing that the combination of 5-HTR 6 antagonist PRX-07034 with low doses of prazosin enhances memory which could be used for the treatment of schizophrenia [164] . In addition, preclinical study proposed that 5-HTR 7 agonists could be useful in the treatment of impaired memory associated with aging or AD [175] . Therapeutic effects of 5-HTR 7 agonists on cognitive symptoms in AD have also been examined in clinical trials [176] . It therefore seems that promnesic or anti-amnesic effects of both 5-HTR 7 agonists and antagonists depend on whether the basal performance is normal or impaired [177] .
The lower expression of 5-HTR 7 in the hippocampus and prefrontal cortex of schizophrenia patients [178, 179] , a positive association between a 5-HTR 7 gene haplotype and the incidence of schizophrenia [180] , the affinity of several atypical antipsychotics for 5-HTR 7 [178, 181] , and the increase of the 5-HTR 7 number in rats treated with typical antipsychotic haloperidol [178] , all suggest the involvement of these 5-HTR in the neurobiological alterations in schizophrenia. In line with the potential contribution of 5-HTR 7 to cognitive dysfunction in schizophrenic patients, a preclinical study suggested an improvement in recognition memory and antipsychotic efficacy after treatment with a 5-HTR 7 antagonist in animal model of psychosis and cognition [182] .
Conclusion
Evidence from the literature suggests that 
